IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2016

Conditions
Leukemia
Interventions
DRUG

IPI-145

75 mg orally twice daily for 4 weeks.

BEHAVIORAL

Follow-up Visit/Call

Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.

Sponsors
All Listed Sponsors
collaborator

Infinity Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER